Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Food companies may be able to satisfy the needs of the growing cohort of GLP-1 medication users while also targeting a ...

The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...

Illegal networks are flooding the market with counterfeit weight loss drugs, posing a serious threat to public health. The ...

A new study reveals that anti-obesity drugs can help kidney transplant recipients with type 2 diabetes reduce the risk of ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

there are effective treatments in the form of multiple FDA-approved anti-obesity medications (AOMs). But for far too many, these medications are inaccessible. Right now, just two percent of people ...

NEW YORK, March 5, 2025 /PRNewswire/ -- Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived ...